By Kamal Choudhury March 26 (Reuters) - Wave Life Sciences shares plunged 58% on Thursday after a higher dose of its experimental obesity drug failed to show a clear improvement at reducing a ...

Wave Life Sciences (NASDAQ:WVE) shares are trading near historic lows after two Wall Street firms cut their price targets ...

Wave Life Sciences (WVE) fell ~57% in the premarket on Thursday as Wall Street reacted to interim data from an early-stage trial for WVE-007, its RNA-based obesity medicine. Citing six-month follow-up ...

Wave Life Sciences Ltd. (NASDAQ:WVE) shares fell 30% Thursday following the company’s announcement of interim Phase 1 data ...

Loomis Sayles, an investment management company, released its fourth-quarter 2025 investor letter for “Small Cap Growth Fund” ...

W hile challenges persist in the short term, there are signs pointing toward long-term growth for life sciences, according to JLL’s 2024 Life Sciences Real Estate Perspective and Cluster Analysis. The ...

T he U.S. life sciences real estate market posted positive net absorption in the fourth quarter even as robust construction completions raised the sector’s vacancy rate to 19.7%, according CBRE’s new ...

When Hurricane Helene tore through Western North Carolina in September 2024, it didn't just uproot trees and wash out roads.

Ed Field is President of BioLabs NC. Mr. Field has 20+ years c-level experience in building and selling numerous early-stage and publicly-traded biotechnology companies. He has been responsible for ...

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's ...

William “Bill” McKeon is the President and Chief Executive Officer of the Texas Medical Center. He is responsible for driving strategic, operational and programmatic initiatives across the Texas ...